Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005579 · ClinicalTrials.gov registry record · Phase 2
Dolastatin 10 in Treating Patients With Indolent Lymphoma, Waldenstrom's Macroglobulinemia, or Chronic Lymphocytic Leukemia
A Phase 2 study of Lymphoma and Leukemia, sponsored by University of Vermont.
- Completed
- Registry status
- Phase 2
- Development phase
- 4
- Study locations
NCT00005579: Completed Phase 2 study of Lymphoma and Leukemia, sponsored by University of Vermont.
NCT00005579 is a Phase 2 study of Lymphoma and Leukemia that has completed, run by University of Vermont. The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00005579, a Phase 2 study of Lymphoma and Leukemia, has completed, sponsored by University of Vermont.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 4
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of dolastatin 10 in treating patients with indolent lymphoma, Waldenstrom's macroglobulinemia, or chronic lymphocytic leukemia.
Interventions
- DRUG dolastatin 10
Study Locations (4)
Maryland
- Marlene and Stewart Greenebaum Cancer Center, University of Maryland - Baltimore
Michigan
- Barbara Ann Karmanos Cancer Institute - Detroit
Ohio
- Arthur G. James Cancer Hospital - Ohio State University - Columbus
Vermont
- Vermont Cancer Center - Burlington
Trial Details
| Field | Value |
|---|---|
| Start Date | 1998-06 |
| Est. Completion | 2003-02 |
| Phase | Phase 2 |
What the finished NCT00005579 record still lists
NCT00005579 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 2 conditions, with Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which dolastatin 10 is the first listed.
NCT00005579 reports a single indexed study location in Maryland, Michigan, Ohio.
Frequently Asked Questions
What is clinical trial NCT00005579 about?
NCT00005579 is a clinical study titled "Dolastatin 10 in Treating Patients With Indolent Lymphoma, Waldenstrom's Macroglobulinemia, or Chronic Lymphocytic Leukemia". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of dolastatin 10 in treating patients with indolent lymphoma, Waldenstrom's macroglobulinemia, or chronic lymphocytic leukemia.
What is the current status of trial NCT00005579?
This trial is currently completed. It is a Phase 2 study. The study started on 1998-06. Estimated completion is 2003-02.
What conditions does trial NCT00005579 study?
This clinical trial studies the following conditions: Lymphoma, Leukemia.
What interventions are being tested in trial NCT00005579?
The interventions under investigation include: dolastatin 10 (DRUG).
Who is sponsoring clinical trial NCT00005579?
This trial is sponsored by University of Vermont, which has 162 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00005579 being conducted?
This trial has 4 study locations across Maryland, Michigan, Ohio, Vermont. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
RECRUITING · Phase 2
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
-
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia